Skip to main content
Premium Trial:

Request an Annual Quote

Synthetic Bio Firm GeneForge Files for Chapter 7 Bankruptcy

NEW YORK (GenomeWeb News) – Synthetic biology instrument firm GeneForge has declared Chapter 7 bankruptcy and will be liquidating its assets.

The firm filed its petition on Dec. 7 in US Bankruptcy Court, Western District of Washington, listing $435,541 in assets and $2.5 million in liabilities.

The company had been based in Redwood City, Calif., but moved to Gig Harbor, Wash., after it was sold last year. On its website GeneForge lists three instrument products, the Coliseum RNA and DNA synthesizer; GF 3900 High-throughput DNA synthesizer; and the GF Deprotection Module High-throughput DNA synthesizer.

The firm also sold consumables.

Its bankruptcy filing lists a single creditor holding secured claims, Midland American Bank, which is claiming $185,000. Creditors holding unsecured claims include Bruce Erickson, the founder of GeneForge, who claims $1.6 million, and Mike Bailey, its President and CEO, who claims $67,875.

Erickson sold GeneForge to Bailey a year ago. This past September, Erickson and others sued Bailey, his wife Candace Bailey, and GeneForge in the Superior Court of the State of California, County of San Mateo alleging breach of contract.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.